Axis Imaging The Script
The Script · Published by Axis Imaging, Melbourne

Sunday 15 November 2026

1 story today

1. TGA warns of risks from injectable peptides used for fitness

Three Synedica peptide products went into the TGA lab labelled as containing TB-500. One of them was called BARBIE KLOW 100mg. The lab found no detectable TB-500 in any of them.

The other two were BPC 157 & TB 500 10mg, marketed as an accelerator of muscle regeneration and injury recovery, and KLOW 80mg, which promises "advanced skin regeneration". Tested Synedica Retatrutide 10 mg products also came up short on retatrutide, with significant variation between samples. Professor Robyn Langham, the TGA's chief medical advisor, flagged anaphylaxis risk and said consumers "can simply not know what is in the substance they are injecting."

Days later, Hepatitis Australia and the Australasian Society of Infectious Diseases added their own warning. Kirby Institute data shows anabolic agents and selected hormones, a category covering steroids, peptides, growth hormone and other performance drugs, rose from 9% of needle and syringe program occasions of service in 2022 to 14% in 2025. Services report growing demand from fitness and bodybuilding crowds.

Hepatitis Australia CEO Lucy Clynes wants practical, non-judgemental messaging. Use new sterile equipment every time, never share it, and dispose of it safely, because shared gear transmits hepatitis B and C. Most pharmacies sell sterile needles.

The recovery and anti-ageing pitch on these products aims squarely at the patients sitting in physio, sports and GP rooms. Anyone injecting them is guessing on both contents and dose, and the labels won't help.

The takeaway: When a patient mentions a recovery stack or a weight-loss injection bought online, ask what it is and where it came from. Anyone holding Synedica product should stop using it, return it to a pharmacy for disposal and report any side effects to the TGA.

Read the source

Also noted

Get tomorrow's issue by email at 6:30am.